The highest clinical utility in NSCLC liquid biopsy was proved in monitoring the level of EGFR gene mutations during the first-line treatment with first (erlotinib, gefitinib) or second (afatinib, dacomitinib) generation of EGFR TKIs [7,122]. Here, EGFR is linked to non-small cell lung carcinoma.